期刊文献+

恶性肿瘤患者紫杉醇药物化疗后心电图异常分析

Analysis of Abnormal Electrocardiogram of Patients with Malignant Tumors after Chemotherapy with Paclitaxel
下载PDF
导出
摘要 目的:分析恶性肿瘤患者在紫杉醇药物化疗前后心电图的改变。方法:记录130例恶性肿瘤患者化疗前、化疗后7 d心电图检查情况,观察窦性心动过速、室性早搏、心房颤动、非特异性ST-T段改变及QRS波群低电压等心电图变化。结果:所有患者接受含紫杉醇药物化疗前均无心电图异常;化疗后,50例患者出现了心电图异常(38.46%),其中<40岁年龄段患者心电图异常发生率明显低于其他各年龄段,差异有统计学意义(P<0.05);化疗第3、4周期后心电图异常发生率明显高于第1、2周期(P<0.05);不同肿瘤类型患者心电图改变比较,差异无统计学意义(P>0.05)。结论:紫杉醇化疗药物对心脏有一定的毒性作用,用其化疗所致的心电图异常发生率随患者年龄的增加而增加,并随化疗疗程的延长呈递增趋势。 Objective:To explore the electrocardiogram changes of patients with malignant tumors before and after chemotherapy with paclitaxel. Method:Recorded the electrocardiograph data of the 130 patients with malignant tumors before and 7 days after chemotherapy,and analyzed the electrocardiogram changes including sinus tachycardia,ventricular premature beat,atrial fibrillation,ST-T segment changes and low QRS voltages,et al.Result:There were no abnormal electrocardiograms before the patients received chemotherapy.50 patients were abnormal electrocardiograms after chemotherapy(38.46%).The incidence of abnormal electrocardiograms in the group aged less 40 years was lower than the other groups(P&lt;0.05).The incidence of abnormal electrocardiogram after the 3rd and 4th chemotherapy cycle was higher than the 1st and 2nd cycle(P&lt;0.05).There were no significant electrocardiogram changes between the patients with different tumors(P&gt;0.05).Conclusion:Chemotherapy with paclitaxel could induce eardiotoxicity.The incidence of abnormal electrocardiogram is increased when patients with age older as well as the chemotherapy prolong.
作者 王智华
机构地区 太原市中心医院
出处 《中外医学研究》 2014年第9期47-48,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 恶性肿瘤 紫杉醇 化疗 心电图 Malignant tumor Paclitaxel Chemotherapy Electrocardiogram
  • 相关文献

参考文献8

二级参考文献28

  • 1Safra T. Cardiac Safety of liposomal anthracyclines [ J ]. Oncologist, 2003,8(Suppl 2) : 17-24.
  • 2Steinberg JS, Cohen A J, Wasserman AG, et al. Acute arrhyth-mogenici- ty of doxorubicin administratlon[J]. Cancer, 1987,60(6) : 1213-1218.
  • 3Steinherz LJ, Steinherz PG, Tan C, et al. Cardiac failure and dysrhthmias 6-19 years after anthracycline thrapy: a series of 15 patients[J]. Med Pediatr Oncol, 1995,24(6) :352-361.
  • 4Von Hoff DD, Layard MW, Base P, et al. Risk factors for doxorubicin- induced congestive heart failure[ J]. Ann Intern Med, 1979, 91 (5) : 710-717.
  • 5Levine MN, Bramwell VH,Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorottracil chemotherapy compared with cyclophosphamide, methothrexate, and fluorouracil in premenopausal women with node-posltive breast cancer[J]. J Clin Oncol, 1998,16 (8) : 2651-2658.
  • 6Gehl J, Boesgaard M, Paaske T, etal. Combined docorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic[ J]. Ann Oncol, 1996,7(7) :687-693.
  • 7Gianni L, Munzone E, Capri G, etal. Paclitaxel by 3-hour infusion in combination with bolus doxorubiein in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose- fmding and sequence-finding study[J]. J Clin Oncol, 1995, 13( 11 ) : 2688-2699.
  • 8Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic charac- terization and in vitro study of the interaction between doxoubicin and paclitaxel in patients with breast cancer[J]. J Clin Oncol, 1997, 15 (5) : 1906-1915.
  • 9Vogel CL, Cobleigh MA,Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2002,20 ( 3 ) : 719-726.
  • 10Leyland-Jones B, Gelmon K, Ayoub JP, etal. Pharmacokinetics, safety, and eficacy of trastuzumab administered every three weeks in combination with paclitaxel [ J ]. J Clin Oncol, 2003,21 (21) : 3965-3971.

共引文献398

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部